Pancreatic Cancer Research

ResearcherLeiden University Medical CenterActive in the last 2 years

Monique Esther van Leerdam

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5719-3208; OpenAlex author ID A5062782199. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 7 papers · 2025: 3 papers · 2026: 4 papers

Papers 20

  1. Optimal upper gastrointestinal surveillance strategies for gastric, small bowel and pancreatic cancer detection in Lynch syndrome. Last author DOI 10.1007/s10689-026-00567-y↗
  2. Pancreatic cancer risk and survival in patients with Lynch syndrome: a nationwide Dutch cohort study. Co-author DOI 10.1016/j.eclinm.2026.103755↗
  3. Longitudinal body composition changes distinguish pancreatic ductal adenocarcinoma from controls in a pre-diagnostic CT cohort. Co-author DOI 10.1016/j.pan.2026.09.008↗
  4. Association Between Computed Tomography-Based AI-Derived Body Composition and Survival in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.14309/ajg.0000000000003896↗
  5. Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis. Last author DOI 10.1007/s10689-025-00512-5↗
  6. Recommendations, evidence and sustainability of screening for pancreatic cancer in high-risk individuals. Co-author DOI 10.1016/j.bpg.2025.101974↗
  7. Protein N-Glycosylation Traits Combined with CA19-9 Accurately Distinguish Pancreatic Cancer Cases From Healthy Controls and Benign Pancreatic Diseases. Co-author DOI 10.1097/mpa.0000000000002517↗
  8. Psychosocial issues of individuals undergoing surveillance for increased risk of melanoma and pancreatic cancer due to a germline CDKN2A variant: A focus group… Co-author DOI 10.1002/jgc4.1820↗
  9. Pancreatic cancer surveillance: Risk stratification of individuals with a germline CDKN2A pathogenic variant. Last author DOI 10.1002/ueg2.12662↗
  10. Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer. Last author DOI 10.1007/s10689-024-00368-1↗
  11. Screening for pancreatic cancer in high-risk individuals using MRI: optimization of scan techniques to detect small lesions. Co-author DOI 10.1007/s10689-024-00394-z↗
  12. Temporal Trends in Body Composition and Metabolic Markers Prior to Diagnosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cgh.2024.03.038↗
  13. The Added Value of Blood Glucose Monitoring in High-Risk Individuals Undergoing Pancreatic Cancer Surveillance. Last author DOI 10.1097/mpa.0000000000002335↗
  14. Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/op.23.00447↗
  15. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis. Last author DOI 10.1053/j.gastro.2023.02.032↗
  16. Hereditary pancreatic cancer. Last author DOI 10.1016/j.bpg.2021.101783↗
  17. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals. Co-author DOI 10.1016/j.pan.2022.03.021↗
  18. Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up. Last author DOI 10.1200/jco.22.00194↗
  19. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer. Co-author DOI 10.3390/ijms22052655↗
  20. Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. Co-author DOI 10.1136/jmedgenet-2012-101277↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Derk C.F. Klatte · 15 shared papers, 2022–2026 · strength 3.24
  2. Aleksander M. Bogdanski · 8 shared papers, 2024–2026 · strength 2.18
  3. Jeanin Elise van Hooft · 10 shared papers, 2022–2026 · strength 2.09
  4. Michael B. Wallace · 8 shared papers, 2022–2026 · strength 1.92
  5. Bert A. Bonsing · 8 shared papers, 2021–2025 · strength 1.39
  6. Yan Bi · 4 shared papers, 2024–2026 · strength 1.00
  7. J. Sven D. Mieog · 5 shared papers, 2022–2026 · strength 0.98
  8. Hans F. A. Vasen · 6 shared papers, 2021–2024 · strength 0.96
  9. Bas Boekestijn · 5 shared papers, 2022–2024 · strength 0.94
  10. Martin N.J.M. Wasser · 5 shared papers, 2022–2024 · strength 0.94
  11. Thomas P. Potjer · 5 shared papers, 2022–2024 · strength 0.90
  12. Marco J. Bruno · 4 shared papers, 2013–2024 · strength 0.61
  13. Manfred Wuhrer · 3 shared papers, 2021–2025 · strength 0.49
  14. Yuri E. M. van der Burgt · 3 shared papers, 2021–2025 · strength 0.49
  15. Wilma E. Mesker · 3 shared papers, 2021–2025 · strength 0.49
  16. Tim Marwitz · 1 shared paper, 2026 · strength 0.43
  17. Douglas L. Riegert‐Johnson · 2 shared papers, 2024–2025 · strength 0.40
  18. Djuna L. Cahen · 2 shared papers, 2022–2024 · strength 0.38
  19. Lydia G. van der Geest · 2 shared papers, 2023–2025 · strength 0.34
  20. Pilar Acedo · 1 shared paper, 2025 · strength 0.33
  21. Che G. Ngufor · 1 shared paper, 2026 · strength 0.29
  22. Koen J.H. Wijsman · 1 shared paper, 2026 · strength 0.28
  23. Hani M. Babiker · 1 shared paper, 2026 · strength 0.28
  24. Hans Morreau · 2 shared papers, 2022–2023 · strength 0.28
  25. Jihane Meziani · 1 shared paper, 2024 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.